Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

ImpediMed Reports Net Loss of $27.57m for the Year to 30 June 2017

11 Oct 2017  |  15:11:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: Appendix 4E - year ended 30 June 2017

ImpediMed reported Net Loss of $27.57m for the year ended 30 June 2017. Revenues from ordinary activities were $6.13m, up 3% from last year. Diluted EPS was (7) cents compared to (8) cents last year. Net operating cash outflow was $25.56m compared to $22.42m last year.

ImpediMed Full Year Results 30 June 2017

Year to 30 June 2017 (A$'000) Year to 30 June 2016 (A$'000)
Revenue 6,133 5,947
Pre-Tax Profit (27,531) (25,980)
Net Profit (27,571) (25,980)
Operating Cash Flow (25,566) (22,422)
Dividend (cents) nil nil
Diluted EPS (cents) (7) (8)
NTA (cents) 15 22
Please click here for full details

See more ASX300 News Announcements